Baldwin Investment Management LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,360 shares of the biopharmaceutical company’s stock after selling 710 shares during the period. Baldwin Investment Management LLC’s holdings in Gilead Sciences were worth $733,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Seizert Capital Partners LLC lifted its position in shares of Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after buying an additional 27,547 shares during the last quarter. Investment Centers of America Inc. lifted its position in shares of Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after buying an additional 1,958 shares during the last quarter. Fagan Associates Inc. lifted its position in shares of Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after buying an additional 845 shares during the last quarter. Capital Asset Advisory Services LLC acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $875,000. Finally, First PREMIER Bank lifted its position in shares of Gilead Sciences by 9.0% in the second quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock valued at $1,524,000 after buying an additional 1,787 shares during the last quarter. 74.28% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/11/05/gilead-sciences-inc-gild-stake-lessened-by-baldwin-investment-management-llc.html.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at $230,656,537.87. The disclosure for this sale can be found here. Insiders have sold a total of 446,819 shares of company stock worth $36,269,486 over the last ninety days. Company insiders own 1.30% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $73.46 on Friday. The company has a market capitalization of $96,012.22, a PE ratio of 7.67, a price-to-earnings-growth ratio of -1.23 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a current ratio of 4.86, a quick ratio of 4.74 and a debt-to-equity ratio of 1.18.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.75 EPS. equities analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.83%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 23.69%.
Several research firms recently weighed in on GILD. Jefferies Group LLC reissued a “hold” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Tuesday, July 11th. Morgan Stanley reissued an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Robert W. Baird reissued an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a report on Thursday, July 13th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price target for the company in a report on Monday, July 17th. Finally, BMO Capital Markets reissued a “hold” rating and set a $72.00 price target on shares of Gilead Sciences in a report on Friday, July 21st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and an average target price of $85.68.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.